• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Paliperidone ER vs Olanzapine for Treatment-Resistant Schizophrenia
Research Update

Paliperidone ER vs Olanzapine for Treatment-Resistant Schizophrenia

June 1, 2023
Zachary Davis
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Zachary Davis. Mr. Davis has no financial relationships with companies related to this material.

REVIEW OF: Wang D et al, J Clin Psychopharmacol 2022;42(4):383–390

STUDY TYPE: Randomized, double-blind, controlled trial

Olanzapine ranks among the most effective antipsychotics in meta-analyses, and this new study compared paliperidone extended release (ER) to olanzapine in treatment-resistant schizophrenia.

This multisite, 12-week trial randomized 86 adults with treatment-resistant schizophrenia (ages 18–45; 77.9% male) to paliperidone ER (n=45; mean dose of 10.73±2.260 mg/day) or olanzapine (n=41; mean dose of 20.49±4.001 mg/day). Researchers defined treatment resistance as failure of at least two antipsychotic trials due to inadequate response, intolerance, or both. Over four weeks, paliperidone ER and olanzapine were titrated in a fixed manner from 3–12 and 5–20 mg/day, respectively. After week four, doses were adjusted based on clinical response.

The primary outcome was baseline-to-endpoint change in psychotic symptom severity measured with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impressions–Severity of Illness Scale. Secondary outcomes included changes in cognitive functioning on the MATRICS Consensus Cognitive Battery and changes in metabolic parameters. Follow-up visits were conducted on weeks one, two, four, eight, and 12. Researchers performed an intention-to-treat analysis and implemented a last-observation-carried-forward imputation strategy for missing data.

On the primary outcome measures, there were no between-group differences in symptom severity improvement. Within-group improvements in PANSS total scores from baseline were observed for both groups by week two of treatment and at all subsequent follow-up visits (p<0.001).

Compared to baseline, there were no differences in cognitive functioning within or between the groups. While weight, waist circumference, and BMI increased within both groups (p<0.001), baseline-to-endpoint waist circumference increase was greater for olanzapine than paliperidone ER (p=0.030).

Eight patients discontinued treatment in each group. The most reported treatment-related adverse events were somnolence and extrapyramidal symptoms in the olanzapine and paliperidone groups.

CARLAT TAKE

This study implies that paliperidone ER may be as effective as olanzapine for treatment-resistant schizophrenia. Paliperidone’s advantages include a favorable side effect profile and availability as a long-acting injection. However, the study’s sample size casts doubt on its ability to detect a true difference between the antipsychotics.

General Psychiatry
KEYWORDS atypical antipsychotics depression olanzapine treatment resistant depression
    Zachary Davis

    Psychiatry Practice Boosters, Fourth Edition (2023)

    More from this author
    www.thecarlatreport.com
    Issue Date: June 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objective, Psychedelics, TCPR, June 2023
    A Psychedelic Primer
    Psychedelic-Assisted Psychotherapy
    Paliperidone ER vs Olanzapine for Treatment-Resistant Schizophrenia
    CME Post-Test, Psychedelics, TCPR, June 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_cover_sm.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • image.png
      General Psychiatry

      Four Natural Therapies for ADHD (with Richard Brown, MD)

      Richard Brown, MD, shows us how to use his top four natural therapies for ADHD: Pycnoginol, Rhodiola rosea, Racetams, American Ginseng.



      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.